{"id":15303,"date":"2012-09-04T10:30:00","date_gmt":"2012-09-04T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutica-canadese-valeant-acquista-medicis-per-26-mld\/"},"modified":"2012-09-04T10:30:00","modified_gmt":"2012-09-04T08:30:00","slug":"farmaceutica-canadese-valeant-acquista-medicis-per-26-mld","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutica-canadese-valeant-acquista-medicis-per-26-mld\/","title":{"rendered":"Pharmaceutical: Canadian Valeant buys Medicis for 2.6 billion $"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">(Il Sole 24 Ore Radiocor) \u2013 Milan, 04 September \u2013 The Canadian pharmaceutical group Valeant has announced the purchase of the US Medicis, specialized in the dermatological sector, for 2.6 billion dollars. This is the fifteenth acquisition completed this year for the Montreal-based company. The transaction, as specified in a note by Valeant, will be finalized within the first half of 2013. According to the agreement signed between the parties, Valeant will buy all Medicis shares, listed on the Nasdaq, at a price of 44 dollars per cash share, with a premium of 39% compared to last Friday&#039;s closing on the New York market (31.87 dollars). The new group that will be formed with this acquisition should reach an annual turnover of 1.7 billion dollars. With this operation, the acquisitions made by Valeant during this year come to an amount of 3.5 billion dollars, according to calculations made by the Canadian newspapers The Globe and Mail.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">red-fla-<\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">(RADIOCOR) 04-09-12 08:25:13 (0050) 5 NNNN<\/p>\n<p><\/span><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>(Il Sole 24 Ore Radiocor) &#8211; Milano, 04 set &#8211; Il gruppo farmaceutico canadese Valeant ha annunciato l&#8217;acquisto della statunitense Medicis, specializzata nel settore dermatologico, per 2,6 miliardi di dollari. Per la societa&#8217; di Montreal si tratta della quindicesima acquisizione conclusa quest&#8217;anno. La transazione, come precisato in una nota da Valeant, sara&#8217; finalizzata entro il &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15303"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15303\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}